[Acute lymphoblastic leukemia, type T: therapeutic results]. 1988

C Melero, and J López, and F García-Muñoz, and C Auray, and M J García, and C Gil, and F Valverde, and J Aracil, and M Bernacer, and T Contra
Hospital 1. de Octubre, Madrid.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D008297 Male Males
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D015459 Leukemia-Lymphoma, Adult T-Cell Aggressive T-Cell malignancy with adult onset, caused by HUMAN T-LYMPHOTROPIC VIRUS 1. It is endemic in Japan, the Caribbean basin, Southeastern United States, Hawaii, and parts of Central and South America and sub-Saharan Africa. ATLL,HTLV I Associated T Cell Leukemia Lymphoma,HTLV-Associated Leukemia-Lymphoma,HTLV-I-Associated T-Cell Leukemia-Lymphoma,Human T Lymphotropic Virus Associated Leukemia Lymphoma,Human T Lymphotropic Virus-Associated Leukemia-Lymphoma,Human T-Cell Leukemia-Lymphoma,Leukemia Lymphoma, Adult T Cell,Leukemia Lymphoma, T Cell, Acute, HTLV I Associated,Leukemia, Adult T-Cell,Leukemia-Lymphoma, T-Cell, Acute, HTLV-I-Associated,T Cell Leukemia Lymphoma, HTLV I Associated,T Cell Leukemia, Adult,T-Cell Leukemia, Adult,T-Cell Leukemia-Lymphoma, Adult,T-Cell Leukemia-Lymphoma, HTLV-I-Associated,Adult T-Cell Leukemia,Adult T-Cell Leukemia-Lymphoma,Adult T-Cell Leukemia-Lymphomas,Adult T-Cell Leukemias,HTLV Associated Leukemia Lymphoma,HTLV-Associated Leukemia-Lymphomas,HTLV-I-Associated T-Cell Leukemia-Lymphomas,Human T Cell Leukemia Lymphoma,Human T-Cell Leukemia-Lymphomas,Leukemia, Adult T Cell,Leukemia-Lymphoma, HTLV-Associated,Leukemia-Lymphoma, HTLV-I-Associated T-Cell,Leukemia-Lymphoma, Human T-Cell,Leukemia-Lymphomas, Adult T-Cell,Leukemia-Lymphomas, HTLV-Associated,Leukemia-Lymphomas, HTLV-I-Associated T-Cell,Leukemia-Lymphomas, Human T-Cell,Leukemias, Adult T-Cell,T Cell Leukemia Lymphoma, Adult,T-Cell Leukemia-Lymphoma, Human,T-Cell Leukemia-Lymphomas, Adult,T-Cell Leukemia-Lymphomas, HTLV-I-Associated,T-Cell Leukemia-Lymphomas, Human,T-Cell Leukemias, Adult

Related Publications

C Melero, and J López, and F García-Muñoz, and C Auray, and M J García, and C Gil, and F Valverde, and J Aracil, and M Bernacer, and T Contra
January 1978, Verhandlungen der Deutschen Gesellschaft fur Innere Medizin,
C Melero, and J López, and F García-Muñoz, and C Auray, and M J García, and C Gil, and F Valverde, and J Aracil, and M Bernacer, and T Contra
October 2021, Bulletin du cancer,
C Melero, and J López, and F García-Muñoz, and C Auray, and M J García, and C Gil, and F Valverde, and J Aracil, and M Bernacer, and T Contra
April 1990, Gematologiia i transfuziologiia,
C Melero, and J López, and F García-Muñoz, and C Auray, and M J García, and C Gil, and F Valverde, and J Aracil, and M Bernacer, and T Contra
January 1998, Ryoikibetsu shokogun shirizu,
C Melero, and J López, and F García-Muñoz, and C Auray, and M J García, and C Gil, and F Valverde, and J Aracil, and M Bernacer, and T Contra
February 2009, Haematologica,
C Melero, and J López, and F García-Muñoz, and C Auray, and M J García, and C Gil, and F Valverde, and J Aracil, and M Bernacer, and T Contra
December 2016, Hematology. American Society of Hematology. Education Program,
C Melero, and J López, and F García-Muñoz, and C Auray, and M J García, and C Gil, and F Valverde, and J Aracil, and M Bernacer, and T Contra
May 2009, Gan to kagaku ryoho. Cancer & chemotherapy,
C Melero, and J López, and F García-Muñoz, and C Auray, and M J García, and C Gil, and F Valverde, and J Aracil, and M Bernacer, and T Contra
May 2014, Oncotarget,
C Melero, and J López, and F García-Muñoz, and C Auray, and M J García, and C Gil, and F Valverde, and J Aracil, and M Bernacer, and T Contra
February 2014, Leukemia,
C Melero, and J López, and F García-Muñoz, and C Auray, and M J García, and C Gil, and F Valverde, and J Aracil, and M Bernacer, and T Contra
April 2021, International journal of molecular sciences,
Copied contents to your clipboard!